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OBJECTIVES: To describe patterns of resource con-
sumption and costs associated with the management of
metabolic abnormalities (MA) among newly diagnosed
HIV+ patients compared to a matched cohort of non-
infected individuals. METHODS: This was a one-year
retrospective database study. Administrative claims from
a managed care organization located in the Western US
were used. Patients 18+ years with a single inpatient or 2
outpatient medical claims with HIV-related ICD-9 codes
(042–044, 079.53, 795.71, V08) or at least 2 pharmacy
claims for antiretroviral therapy for >30 days between
July 1999 and June 2000 were eligible. Patients with
claims for HIV or MA prior to index date were excluded.
In addition, a matched control cohort was identiﬁed.
Patients were matched 3 :1 based on age, gender and
state. Outcomes were MA-related prescriptions, ER visits,
physician ofﬁce visits, hospitalizations, and associated
costs. Statistical analysis was conducted using chi-square
or t-test as appropriate. RESULTS: One thousand three
hundred sixty-eight controls and 456 HIV+ patients were
eligible. Mean age was 40 years, and 86% were males.
The HIV+ patients had a higher Charlson Comorbidity
Index of 0.46 vs. 0.05 (p = 0.0001). More HIV+ patients
had a physician visit (12.5% vs. 10.7%; p = NS), hospi-
talization (2.6% vs. 0.9%; p = 0.004), and ER visit (2.2%
vs. 0.1%; p < 0.0001) for MA. Odds ratio for MA-related
hospitalizations and ER visits in the HIV vs. control
cohorts were 3.1 (95% CI: 1.4–6.8) and 15.3 (95% CI:
3.3–70.2), respectively. Population level mean medical
(physician visits, ER visits, hospitalizations) and phar-
macy costs for MA in the HIV+ vs. control cohorts were
$473.93 vs. $128.60 (p = 0.03); $42.80 vs. $13.69 (p =
0.0005), respectively. CONCLUSIONS: The one-year
resource consumption and costs related to MA were sig-
niﬁcantly higher among the HIV+ cohort. The occurrence
of MA in HIV+ patients was associated with a higher
burden than in control patients with the greatest impact
on MA-related hospitalization and ER visits.
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OBJECTIVES: We investigate the cost effectiveness of
counseling to improve adherence to highly active anti-
retroviral therapy (HAART) regimens for HIV infection.
Low adherence may lead to drug-resistant HIV strains
and poor health outcomes. METHODS: We develop a
dynamic compartmental model of HIV progression that
accounts for multiple treatment regimens (three HAART
regimens followed by salvage therapy), four levels of
resistance to HAART, and three levels of adherence 
to HAART (high, low, and very low). We assume that
61% of high-adherence individuals remain in the high-
adherence state at the end of each year. We assume a
counseling session by a trained pharmacist is given upon
initiation of HAART and following all treatment failures
(deﬁned as viral load rebound). We assume that such
counseling costs $100 per session, and increases retention
in the high-adherence state. We evaluate the cost effec-
tiveness of counseling by simulating over a ten-year time
horizon. RESULTS: If the counseling sessions increase
retention in the high-adherence state to 65%, then coun-
seling costs $83,700 per QALY gained; if they increases
the rate to 75%, then counseling costs $19,500 per QALY
gained. If the rate at which individuals switch from low
to high adherence in the absence of any interventions is
greater than 10% per year then the cost effectiveness of
counseling is relatively insensitive to the improvement in
adherence. The cost effectiveness of improved adherence
is very sensitive to changes in the cost of the counseling
sessions. CONCLUSIONS: Counseling to improve adher-
ence to HAART is likely to be cost effective if it increases
the high-adherence retention to at least 75% per year.
Additional empirical studies are needed to determine the
effectiveness of other methods of improving adherence,
such as electronic reminders and directly observed
therapy. The dangers posed by drug-resistant HIV strains
makes this an important issue for further study.
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OBJECTIVES: Despite frequently causing serious illness
in adolescents, immunization programmes against per-
tussis have been restricted to children <7. We estimated
the economic impact of introducing a booster dose of
acellular pertussis vaccine in two Canadian provinces
(Ontario and Québec) using different vaccination sched-
ules. METHODS: We conducted a cost effectiveness
analysis using a predictive spreadsheet model with ado-
lescents aged 12 (cohorts of 88,000 in Québec and
